Global Molybdenum 99 Market 2026 – 2035

Global Bio-based Feedstocks market size is predicted to be approx. USD 5.17 billion in 2025 and is forecast to reach USD 5.40 billion in 2026 and then almost USD 8.33 billion by 2035 with a CAGR of 4.89% over the forecast period 2026 to 2035. The market is on a healthy growth trajectory, and this is driven by the rise in demand for high-end Nuclear Medicine diagnostics, rise in the prevalence of chronic diseases such as Cancer and cardiovascular issues.

Molybdenum-99 is an essential medical isotope required for manufacturing Technetium-99m (Tc-99m), which is largely used in diagnostic medical imaging procedures such as SPECT scans. Its shorter half-life and higher imaging efficacy render it essential for live functional assessment of organs in modern healthcare infrastructure. Growing utilization of Nuclear imaging for diagnosing Cancer, cardiovascular diseases, and Neurological diseases and increasing investment in radio pharmaceutical manufacturing facilities globally.

Impact of US-Iran War on the Molybdenum-99 Market

The production of enriched uranium targets, radioisotope processing materials, specialized containers, and the nuclear medicine logistics involved in molybdenum-99 production has been affected by the war between the United States and Iran. As a result of the increased geopolitical uncertainty, transportation security needs and costs, energy costs, and cross-border logistics costs have also risen, posing operational challenges and cost pressures for the molybdenum-99 market and associated medical isotope supply chain.

Market Highlight

• Asia Pacific dominated the Mo-99 market in 2025 with a 38.4% market share, owing to fast development of nuclear medicine infrastructure, increasing adoption of SPECT imaging and growing investment in diagnostic health systems. The North America market is projected to expand at a CAGR of approximately 4.6% from 2026-2035, attributed to high capabilities in nuclear medicine, the highest volume of cardiac and cancer SPECT procedures and a strong foothold in radiopharmaceutical manufacturers.

• The reactor-based production holds more than 52.6 %market share by production method in 2025 as it has a strong capability of producing large volumes of isotopes and providing supply stability of Tc-99m generators.

• The accelerator-based production is anticipated to experience the highest CAGR of approximately 6.4% from 2026 to 2035 by production method, owing to growing investments in non-reactor-based technologies of isotope production and the security concerns of its supply.

• Diagnostic imaging (SPECT imaging) held about 44.28 % of the market share by application in 2025 owing to its extensive use in nuclear medicine procedures, while oncology diagnostics and cardiology imaging are likely to witness the fastest CAGR owing to the high prevalence of diseases.

• Hospitals held almost 43.8% market share in 2025 by end-use as they hold more importance in nuclear imaging procedures, while diagnostic imaging centers are estimated to grow with the highest CAGR owing to outsourcing of imaging services and increasing diagnostic imaging centers.

Significant Growth Factors

• Increased demand for Nuclear Diagnostic Imaging in Oncology and Cardiology: Growth in the molybdenum-99 market is mostly propelled by the increased prevalence of cancer and heart disease across the globe. The development and subsequent utilization of an increasing number of cancer treatment procedures are raising the demand for nuclear diagnostic imaging. It must be noted that more than 30 to 35 million diagnostic imaging procedures every year use Technetium-99m (Tc-99m), derived from the radioisotope molybdenum-99. Spect imaging equipment in clinics and hospitals has gained prominence in this sphere, leading to a sharp rise in the demand for a secure supply of molybdenum-99.

• Development of radiopharmaceutical Production Infrastructure and Expansion of Nuclear Medicine: The market growth is fueled by the expanding radiopharmaceutical production facility and nuclear medicine infrastructure globally. Many countries are looking for ways to strengthen their self-reliance over nuclear isotope production with increased efforts towards setting up the facility in their own country. Many new production techniques, such as the production of radioisotopes using LEU-based targets and the acceleration-driven production methods are being developed and tested to establish a steady supply of the radioisotope in the global market.

• The Move Towards Non-Reactor Based Production Systems: Another trend defining the molybdenum-99 market is the movement towards using cyclotrons and linear accelerator-based production methods rather than the conventional method of nuclear reactor-based production. These modern techniques decrease nuclear waste and assure a consistent supply of the radioisotopes in the market. Governments and organizations are funding the creation of these next-generation nuclear medicine equipment and technologies with an intention to combat the current global nuclear isotope shortage and reactor shutdown issues in an endeavor to promote global healthcare.

• Increasing Use of Precision Medicine and Sophisticated Diagnostic Procedures: Precision medicine has taken center stage today as an efficient tool for the targeted diagnosis and treatment of many diseases. Early diagnosis of critical illnesses can now be carried out with increased accuracy by use of nuclear diagnostic procedures. Mo-99-based Tc-99m radiopharmaceuticals allow real-time visualization of the heart, kidney and bone and provide better resolutions. The use of hybrid nuclear diagnostic tools such as SPECT/CT also further boosts their efficacy, thereby increasing the market demand for the highest quality of nuclear isotopes worldwide.

Which are the Major Developments That are fueling the Molybdenum 99 Market today?

• Advances in Alternative Medical Isotope Production Technologies: In Molybdenum-99, it is an advancement in production methodologies – alternative production to traditional methods like reactors. Technologies such as cyclotrons and accelerator-driven systems aim to meet the gap in the market of Medical Isotope due to outdated reactors worldwide. Countries like Canada, the Netherlands and Australia are focusing on in-house production and hence are investing in developing decentralized production facility centers which would support global medical imaging applications.

• Increase in Domestic Radiopharmaceutical Manufacturing Capabilities: Governments and many private bodies are showing interest in radiopharmaceutical production facilities so that the dependence on limited manufacturers all across the globe will come down. New processing facilities are developed to produce Tc-99m generators from decay of Mo-99. The increasing infrastructure supports the demand of this generator from North America and the Asia Pacific in terms of distribution as well as storage facilities.

• Molybdenum-99 Integration in Latest Nuclear Imaging Technologies: SPECT/CT and SPECT/PET systems are the two new generations of imaging technologies adopted in the medical world that greatly improve the use of Molybdenum-99 in the medical field. These advanced imaging systems offer a higher degree of accuracy in scanning and in detecting diseases. Therefore, there is an increased demand for Molybdenum-99 for the same.

• Reactor Modernization and Emphasis on Supply Chain Security in Global Market: Reactor shutdowns and Geopolitical supply risks have necessitated important initiatives aimed at achieving supply chain security of Molybdenum-99. New reactors are being installed across several countries and plans for new production systems for alternative generation of isotopes have been drawn by many governments. The inter-country cooperation to guarantee continuous supply of isotope for medical diagnostics also highlights the growing strategic importance of Mo-99.

Category Wise Insights

By Production Method

Why is Reactor-Based Production the leader?

Reactor-based production takes up a large share of the market for molybdenum-99. This is because reactor-based production has a long history of producing the radioisotope in a large-scale production facility and in a highly pure form which is essential for diagnostic applications. Most of the Mo-99 in the world is produced using research reactors, and the majority of the demand is for producing technetium-99m generators used for SPECT imaging. However, despite the fact that in some regions, most reactors are old, the market share of reactor-based production is still high due to its proven history and large-scale capabilities.

Accelerator-based production is the fastest growing part of the market. This is because there have been large investments in alternative isotope production systems in an attempt to decrease dependency on nuclear reactors. Cyclotron-based production is becoming an important aspect for the production of radioisotopes that will be available at the point of care. Fission-based LEU (low enriched uranium) target production is also expanding due to the increased tendency of shifting from using HALEU to using LEU in nuclear reactors to produce radioisotopes for medical applications.

By Application

Why is diagnostic imaging dominating the market?

Diagnostic imaging takes up the largest share of the market for molybdenum-99, since a very high amount of nuclear medicine imaging is carried out in a diagnostic imaging procedure and SPECT imaging forms a large part of it. Mo-99 is essential in creating real time images that can provide the clinician with information regarding the organs which is vital for early detection of chronic diseases in Cardiology, Oncology, Neurology etc. Due to the increasing demand for health care and increase in the number of patients suffering from chronic diseases this part is gaining higher momentum.

Oncology imaging and cardiology imaging are the fastest growing segments within the application. This is because of the increasing number of people affected by cancer and heart diseases globally. Neurology imaging is growing at a constant pace due to the rise in the number of patients affected with diseases such as Alzheimer's and other neurodegenerative disorders. Bone scanning maintains stable growth in its segment. Others such as kidney and thyroid imaging also contribute.

By End-Use

Why are hospitals leading the market?

Hospitals are the largest consumers of molybdenum-99. The majority of nuclear imaging studies performed using SPET scanners are done in a hospital-based setting and usually done by the hospital's own diagnostics department and radiology unit which is equipped with an advanced medical system. The radiopharmaceuticals used in SPECT imaging are predominantly injected in the hospital environment with advanced setup.

Diagnostic imaging centers constitute the fastest-growing part within the end use sector as, there is an increase in outsourcing of imaging services, and the rise in the number of freestanding diagnostic imaging centers is contributing to its growth. The other major players include the radiopharmaceutical companies which will manufacture the isotope in the required quantities. Research institutes are increasing their consumption of the isotope for use in clinical research and advancement in the fields of nuclear medicine. Specialty clinics and ambulatory care centers are also growing in the end-use sectors to provide diagnostic procedures to patients in outpatient settings.

Report Scope

Regional Analysis

Asia Pacific Molybdenum 99 Market: What is the Size?

The Molybdenum 99 market in the Asia Pacific is predicted to reach $1.99 billion in 2025, and grow to nearly $3.19 billion in 2035 with a CAGR of 4.84% between 2026 and 2035.

Asia Pacific: What will Make it Dominate the Market in 2025?

The Asia Pacific region is anticipated to lead the market for molybdenum-99 due to a proliferation in the network of nuclear medicine infrastructure, a high prevalence of SPECT imaging and the growing rate of heart disease and cancer among nations such as China, India, Japan and South Korea. High growth in diagnostic imaging centers and nuclear medicine departments within hospitals has been noticed across the Asia Pacific, alongside growing investment from the government in advancing the infrastructure of health facilities, developing radioisotope production sites and enhancing the access to diagnostic imaging technologies, which are driving demand for molybdenum-99-based radiopharmaceuticals.

China Market: Key Trends

China serves as a significant market for molybdenum-99 on the back of a large number of patients and its fast-growing nuclear medicine framework. The government has been investing heavily to produce domestic radioisotopes and curb the dependency on imports in order to improve security within the health sector. The number of SPECT/CT units being installed across hospitals and increasing applications of these machines for cancer and cardiac diagnosis are stimulating demand. Moreover, the development of the medical imaging industry and a focus on research for radiopharmaceuticals are prompting the use of Mo-99 across diagnostic centers.

North America: What is the Reason for Consistent Growth?

A constant rise has been seen in the molybdenum-99 market across North America due to a developed nuclear medicine framework and a high demand for diagnostic imaging. A well-established system of hospitals and diagnostic centers that perform numerous SPECT scans for cancer and cardiac diagnoses are the primary reasons behind this. Upgrades to older systems within this framework and steady improvement in the supply chains of medical isotopes alongside a well-functioning reimbursement framework are further pushing this steady growth.

U.S. Market: What is its Size?

The U.S. Molybdenum 99 market is expected to be around $1.71 Billion by 2025 and grow with a CAGR of 6.43% during the period from 2026-2035.

U.S. Market: Key Trends

The U.S. Market is characterized by a high rate of demand for nuclear imaging scans, primarily for the diagnoses of cardiac ailments and cancer. Millions of SPECT scans are performed in the U.S. On an annual basis which leads to high usage of Mo-99. This sustained growth in demand for Mo-99 is propelled by the presence of leading healthcare facilities and ongoing upgrades for nuclear reactors and cyclotron-based isotope production facilities in addition to the growing incidence rates of various diseases. Government-backed research to ensure the supply chains of isotopes across the country has further motivated the creation of new domestic isotope production plans.

Europe: What is the Reason for the Implementation of Advanced Nuclear Medicine Systems?

The European region represents a strong market for molybdenum-99 owing to a highly developed infrastructure for healthcare alongside widespread application of nuclear imaging techniques. Diagnostic imaging centers and hospitals have established reliable networks of diagnostic centers where SPECT imaging plays a pivotal role in early detection of various disorders. An increase in incidences of cardiovascular diseases and cancer and strong support from various governments toward nuclear medicine programs have led to increased usage of molybdenum-99. European countries have, furthermore, been investing heavily into non-reactor-based production of medical isotopes to provide sustained long-term supplies.

Germany Market: Key Trends

Germany plays a very important role in the European molybdenum-99 market owing to a strong nuclear medicine research framework along with a highly advanced health system. SPECT imaging usage in hospitals and specialized health facilities across Germany is high. Investments into the development of radiopharmaceuticals and collaborations among health institutions and research centers are fuelling new innovations in the field. Germany’s concentration on precise diagnosis of diseases and their early detection is helping the steady market growth of Mo-99.

Middle East & Africa Region: Why will it Grow?

The Middle East and Africa region is set to experience a steady increase in the molybdenum-99 market due to improvements in the available health infrastructure and the growing use of advanced technologies to help in diagnoses. Countries such as the U.A.E., Saudi Arabia, and South Africa have invested in developing a strong network of nuclear medicine facilities and modern hospitals, while widespread awareness about early diagnostics and the increasing burden of cancer and heart disease combined with greater availability of SPECT services have boosted the growth of the market, with the region expected to be quick to adopt radiopharmaceutical diagnostics in the years to come.

Top Players in the Market and Their Offerings

• NRG

• Curium

• NTP Radioisotopes

• ANSTO

• NorthStar Medical Radioisotopes

• SHINE Technologies

• IRE (Institut des Radioéléments / IRE-Elit)

• Lantheus Medical Imaging

• Eckert & Ziegler

• Rosatom State Atomic Energy Corporation

• Others

Key Developments

The market has undergone a huge amount of change with the actors in the market striving to optimize production facilities and expand product portfolios.

• NorthStar Medical Radioisotopes announced in March 2026 plans to upgrade their US-based, non-uranium-based facility for the production of Molybdenum-99 isotopes. In a move to minimize their reliance on imported isotopes and bolster the United States' domestic supply of isotopes for SPECT imaging, the plan promises substantial increases in production capacity while simultaneously guaranteeing supply to hospitals and diagnostics centers.

• A revised generator system was announced in December 2025 by Curium Pharma for the production of Molybdenum-99/Tc-99m isotopes. This innovation has been produced with increased extraction efficiency and with a reduction in the waste products, also serving to increase efficiency in the nuclear medicine departments with respect to clinical workflow.

They also claim that the system will serve to increase patient throughput with respect to cardiology, oncology, etc. The moves, in both of the above, help these companies secure a stronger position in the marketplace and also capitalize on global trends towards the use of disposable and minimally invasive surgery.

The Molybdenum 99 Market is segmented as follows:

By Production Method

• Reactor-Based Production

• Accelerator-Based Production

• Cyclotron-Based Production

• Fission-Based LEU Targets

By Application

• Diagnostic Imaging (SPECT Imaging)

• Oncology Diagnostics

• Cardiology Imaging

• Neurology Imaging

• Bone Scanning

• Others

By End-Use

• Hospitals

• Diagnostic Imaging Centers

• Specialty Clinics

• Research Institutes

• Radiopharmaceutical Companies

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America